基础医学与临床 ›› 2018, Vol. 38 ›› Issue (8): 1158-1162.

• 短篇综述 • 上一篇    下一篇

二甲双胍调控miRNAs抑制恶性肿瘤机制研究进展

刘萤照,冯雁,王琪   

  1. 广西医科大学
  • 收稿日期:2018-01-15 修回日期:2018-04-29 出版日期:2018-08-05 发布日期:2018-07-24
  • 通讯作者: 王琪 E-mail:qi_catcat@163.com
  • 基金资助:
    国家自然科学基金;广西医科大学区域性高发肿瘤早期防治研究教育部重点实验室自主课题

Advance in the mechanism of metformin regulating miRNAs to suppress malignant tumors

  • Received:2018-01-15 Revised:2018-04-29 Online:2018-08-05 Published:2018-07-24
  • Contact: Qi Wang E-mail:qi_catcat@163.com
  • Supported by:
    Natural Science Foundation of China

摘要: 2型糖尿病治疗药物二甲双胍通过调控多种微小RNA(miRNAs)抑制肿瘤细胞增殖、侵袭迁移、上皮间充质转化、有氧糖酵解、肿瘤血管形成和促进凋亡等生物学过程,抑制胰腺癌、胆管癌、前列腺癌、卵巢癌、乳腺癌、子宫内膜癌、口腔癌、胃癌和肺癌等多种恶性肿瘤的发生与发展。研究二甲双胍调控的关键miRNAs,阐明其抑制肿瘤的完整机制,对肿瘤防治和新药研发都具有十分重要的意义。

关键词: 二甲双胍, miRNA, 恶性肿瘤, 机制

Abstract: Type 2 diabetes drug metformin could inhibit proliferation, migration, epithelial mesenchymal transformation, aerobic glycolysis, angiogenesis and promote apoptosis through regulating multiple miRNAs in malignant tumors such as pancreatic cancer, cholangiocarcinoma, prostate cancer, ovarian cancer, breast cancer, endometrial cancer, oral cancer, stomach cancer and lung cancer. Further exploring the key miRNAs regulated by metformin, will help clarifying the underlying mechanism of metformin’s tumor inhibition effect and developing new therapies for treating cancer.

Key words: metformin, miRNA, malignant tumors, mechanism

中图分类号: